Ha habido 50 transacciones internas recientes registradas para Xilio Therapeutics, Inc. (XLO), incluyendo 36 compras y 11 ventas. El total de compras internas fue valorado en $14.86M y el total de ventas internas en $12.1M.
Internos destacados con actividad reciente incluyen Shannon James Samuel, Gilead Sciences, Inc., Brennan Kevin M.. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — XLO
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-03-26 |
Shannon James Samuel |
Director |
Compra Informativa |
5,000 |
$8.79 |
$43.95K |
10,000 |
| 2026-02-13 |
Gilead Sciences, Inc. |
10 Percent Owner |
Compra Informativa |
3,739,000 |
$0.00 |
$373.90 |
40,384,266 |
| 2026-01-02 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Venta Informativa |
1,826 |
$0.64 |
$1.17K |
6,371 |
| 2026-01-02 |
Frankenfield Christopher James |
Chief Financial Officer |
Venta Informativa |
7,030 |
$0.64 |
$4.52K |
24,766 |
| 2026-01-01 |
Russo Rene |
President and CEO |
Ejercicio de Opciones (Venta) |
44,250 |
- |
- |
88,500 |
| 2026-01-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Ejercicio de Opciones |
5,000 |
- |
- |
8,197 |
| 2026-01-01 |
Frankenfield Christopher James |
Chief Financial Officer |
Ejercicio de Opciones |
19,375 |
- |
- |
31,796 |
| 2026-01-01 |
Luptakova Katarina |
Chief Medical Officer |
Ejercicio de Opciones |
16,625 |
- |
- |
33,250 |
| 2025-12-31 |
Russo Rene |
President and CEO |
Concesión de RSU |
1,500,258 |
$0.84 |
$1.26M |
1,500,258 |
| 2025-12-31 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Concesión de RSU |
95,221 |
$0.84 |
$80.08K |
95,221 |
| 2025-12-31 |
Frankenfield Christopher James |
Chief Financial Officer |
Concesión de RSU |
668,789 |
$0.84 |
$562.45K |
668,789 |
| 2025-12-31 |
Luptakova Katarina |
Chief Medical Officer |
Concesión de RSU |
451,885 |
$0.84 |
$380.04K |
451,885 |
| 2025-11-26 |
Gilead Sciences, Inc. |
10 Percent Owner |
Ejercicio de Opciones (ITM) |
13,335,000 |
$0.75 |
$10M |
- |
| 2025-11-21 |
Russo Rene |
President and CEO |
Devolución de Acciones |
135,134 |
$11.69 |
$1.58M |
- |
| 2025-11-21 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Devolución de Acciones |
20,000 |
$1.08 |
$21.6K |
- |
| 2025-11-21 |
Frankenfield Christopher James |
Chief Financial Officer |
Devolución de Acciones |
150,000 |
$2.75 |
$412.5K |
- |
| 2025-11-21 |
Luptakova Katarina |
Chief Medical Officer |
Devolución de Acciones |
25,000 |
$2.79 |
$69.63K |
- |
| 2025-06-17 |
Shannon James Samuel |
Director |
Compra Informativa |
25,000 |
$0.69 |
$17.22K |
70,000 |
| 2025-06-16 |
Shannon James Samuel |
Director |
Compra Informativa |
45,000 |
$0.69 |
$30.87K |
45,000 |
| 2025-06-16 |
Russo Rene |
President and CEO |
Compra Informativa |
36,289 |
$0.68 |
$24.68K |
281,172 |
| 2025-06-11 |
Clancy Paul J |
Director |
Concesión de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Shannon James Samuel |
Director |
Concesión de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Bonstein Sara |
Director |
Concesión de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Brennan Aoife |
Director |
Concesión de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Ross Robert W. |
Director |
Concesión de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Rossi Christina |
Director |
Concesión de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Xu Yuan |
Director |
Concesión de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Curran Daniel J. |
Director |
Concesión de RSU |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-10 |
Bello Akintunde Olatokumbo |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-06-10 |
Bello Akintunde Olatokumbo |
Director |
Concesión de RSU |
62,000 |
$0.70 |
$43.4K |
62,000 |
| 2025-06-05 |
Gilead Sciences, Inc. |
10 Percent Owner |
Compra Informativa |
13,335,000 |
$0.75 |
$10M |
13,335,000 |
| 2025-04-15 |
Russo Rene |
President and CEO |
Concesión de RSU |
190,000 |
$0.71 |
$135.28K |
190,000 |
| 2025-04-15 |
Frankenfield Christopher James |
Chief Financial Officer |
Concesión de RSU |
75,000 |
$0.71 |
$53.4K |
75,000 |
| 2025-01-02 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Venta Informativa |
1,803 |
$0.98 |
$1.77K |
3,197 |
| 2025-01-02 |
Frankenfield Christopher James |
Chief Financial Officer |
Venta Informativa |
6,954 |
$0.98 |
$6.84K |
12,421 |
| 2025-01-01 |
Russo Rene |
President and CEO |
Ejercicio de Opciones (Venta) |
44,250 |
- |
- |
132,750 |
| 2025-01-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Ejercicio de Opciones |
5,000 |
- |
- |
5,000 |
| 2025-01-01 |
Frankenfield Christopher James |
Chief Financial Officer |
Ejercicio de Opciones |
19,375 |
- |
- |
19,375 |
| 2025-01-01 |
Luptakova Katarina |
Chief Medical Officer |
Ejercicio de Opciones |
16,625 |
- |
- |
16,625 |
| 2025-01-01 |
Russo Rene |
Officer |
Desconocido |
- |
- |
- |
- |
| 2024-12-18 |
Gilead Sciences, Inc. |
10 Percent Owner |
Compra Informativa |
1,759,978 |
$1.04 |
$1.83M |
9,105,451 |
| 2024-10-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Concesión de RSU |
26,000 |
$0.75 |
$19.5K |
26,000 |
| 2024-08-03 |
Frankenfield Christopher James |
Chief Operating Officer |
Concesión de RSU |
52,000 |
$0.90 |
$46.54K |
52,000 |
| 2024-06-14 |
Clancy Paul J |
Director |
Concesión de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Bonstein Sara |
Director |
Concesión de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Ross Robert W. |
Director |
Concesión de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Rossi Christina |
Director |
Concesión de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Xu Yuan |
Director |
Concesión de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Curran Daniel J. |
Director |
Concesión de RSU |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-13 |
Shannon James Samuel |
Officer |
Desconocido |
- |
- |
- |
- |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
